- Home
- CEIX vs DNLI Comparison
CEIX vs DNLI Comparison
Compare CEIX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEIX
- DNLI
- Stock Information
- Founded
- CEIX 1864
- DNLI 2013
- Country
- CEIX United States
- DNLI United States
- Employees
- CEIX N/A
- DNLI N/A
- Industry
- CEIX Coal Mining
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEIX Energy
- DNLI Health Care
- Exchange
- CEIX Nasdaq
- DNLI Nasdaq
- Market Cap
- CEIX 3.6B
- DNLI 3.3B
- IPO Year
- CEIX 2017
- DNLI 2017
- Fundamental
- Price
- CEIX $103.91
- DNLI $21.56
- Analyst Decision
- CEIX Strong Buy
- DNLI Strong Buy
- Analyst Count
- CEIX 2
- DNLI 11
- Target Price
- CEIX $139.00
- DNLI $40.40
- AVG Volume (30 Days)
- CEIX 459.3K
- DNLI 965.5K
- Earning Date
- CEIX 02-04-2025
- DNLI 11-06-2024
- Dividend Yield
- CEIX 0.24%
- DNLI N/A
- EPS Growth
- CEIX N/A
- DNLI N/A
- EPS
- CEIX 13.65
- DNLI N/A
- Revenue
- CEIX $2,244,524,000.00
- DNLI N/A
- Revenue This Year
- CEIX N/A
- DNLI N/A
- Revenue Next Year
- CEIX $36.53
- DNLI $420.35
- P/E Ratio
- CEIX $7.59
- DNLI N/A
- Revenue Growth
- CEIX N/A
- DNLI 204.74
- 52 Week Low
- CEIX $75.43
- DNLI $14.56
- 52 Week High
- CEIX $134.59
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CEIX 24.40
- DNLI 31.61
- Support Level
- CEIX $114.01
- DNLI $22.61
- Resistance Level
- CEIX $118.40
- DNLI $24.15
- Average True Range (ATR)
- CEIX 4.24
- DNLI 1.12
- MACD
- CEIX -2.28
- DNLI -0.19
- Stochastic Oscillator
- CEIX 2.09
- DNLI 13.47
About CEIX CONSOL Energy Inc.
CONSOL Energy Inc is a producer and exporter of high-BTU bituminous coal. It owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators. Its operating segment includes PAMC (Pennsylvania Mining Complex) and CONSOL Marine Terminal. The company generates maximum revenue from the PAMC segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.